BD Picks Up NGS Technology Firm GenCell Biosystems

October 14, 2014

Becton, Dickinson and Company said Monday that it has acquired GenCell Biosystems, an Irish biotech firm, for an undisclosed sum. GenCell develops technologies for biological analysis protocols, such as library preparations of next-generation sequencing and genotyping.

The acquisition provides BD entry into the NGS market, a fast-growing segment with the potential to have a significant impact on healthcare, says Linda Tharby, group president for BD.

The deal also gives BD a differentiated platform on which to grow its genomics offerings and address unmet needs, Tharby says.

Kieran Curran, CEO and founder of GenCell, says the deal will allow the Limerick, Ireland, company to introduce additional transformative innovations in NGS-related segments.

GenCell maintains a marketing, sales and service presence in Madison, Wis. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.